Abstract: The present invention provides radioactive glass microspheres for embolization and a preparation method and an application thereof. A nuclide oxide and a foaming agent are added into a glass matrix, blended and uniformly mixed for making the foaming agent decomposed and vaporized at a high temperature to generate bubbles, so as to prepare the radioactive glass microspheres for embolization with cavities. The radioactive glass microspheres for embolization have a density of 1.4-2.3 g/cm3, a nuclide loading rate of 15-40 wt % and a higher and more stable radiation dose, can achieve better distribution and deposition effects in liver blood vessels after injection, and can achieve a better therapeutic effect for hepatocellular carcinoma (HCC).

Abstract: A low-heat-loss operation method of a line-focusing heat collection system and the line-focusing heat collection system are provided. The method includes the following steps. Solar energy is utilized to preheat a collector tube in an empty tube state, so that the collector tube is in a preheating mode. After a set preheating temperature is reached, a heat transfer working medium is injected into the collector tube. In the injection process of the heat transfer working medium, an injection section of the collector tube is converted into a focusing mode from a preheating mode. After heat collection is finished, the circulation of the heat transfer working medium is stopped, and the focusing mode of the collector tube is kept. In the drainage process of the heat transfer working medium, an emptying section of the collector tube is converted into a light heat-tracing mode from a focusing mode.

Abstract: A screw conveyor having auxiliary blades (10), and a screw discharge decanter centrifuge. A hollow internal cylinder (4) is provided with a tapered section (11) and a straight section (7). Screw blades (6) are provided on the periphery of the inner cylinder (4), and several auxiliary blades (10) are provided between the screw blades (6), wherein the width of the auxiliary blades (10) is smaller than the pitch of the screw blades (6). Two adjacent auxiliary blades (10) are arranged in a staggered manner in a screw passage space to form a serpentine flow passage (15).

Abstract: Disclosed are methods, systems, and non-transitory computer-readable medium for generating recommendations regarding products. A method may include determining a set of content features including one or more product attributes; determining a set of latent features; receiving a query user identifier and a query product identifier; determining a feature vector associated with the query user identifier and the query product identifier based on the set of content features and the set of latent features; determining one or more model coefficients for a linear model; and utilizing the linear model to determine a fit score for the query user identifier and the query product identifier.

Abstract: Disclosed herein are methods for analyzing quantitative expression values of biomarkers of a biomarker panel for determining multiple sclerosis disease activity (e.g., multiple sclerosis disease progression) in a human subject. Further disclosed herein are kits for measuring quantitative expression values of the markers as well as computer systems and software embodiments of predictive models for determining multiple sclerosis disease activity (e.g., multiple sclerosis disease progression) in human subjects based on the quantitative expression values of the markers.

Abstract: Disclosed are methods, systems, and non-transitory computer-readable medium for generating recommendations regarding products. A method may include determining a set of content features including one or more product attributes; determining a set of latent features; receiving a query user identifier and a query product identifier; determining a feature vector associated with the query user identifier and the query product identifier based on the set of content features and the set of latent features; determining one or more model coefficients for a linear model; and utilizing the linear model to determine a fit score for the query user identifier and the query product identifier.

Abstract: The present invention discloses a glass material, and a preparation method and a product thereof. The glass material contains a lithium salt crystalline phase and a phosphate crystalline phase. For the entire material, the crystallinity is 40-95%, the lithium salt crystalline phase accounts for 40-90 wt % of the entire material, and the phosphate crystalline phase accounts for 2-15 wt % of the entire material, wherein the lithium salt crystalline phase is one or more of lithium silicate, lithium disilicate and petalite, and the phosphate crystalline phase is aluminum phosphate or/and aluminum metaphosphate. After the glass material of the present invention is toughened, the Vickers hardness (Hv) is 900 kgf/mm2 or above. The glass material or a substrate of the present invention is suitable for protective members such as mobile terminal equipment and optical equipment and has high hardness and strength.

Abstract: An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.

Abstract: The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.

Abstract: Disclosed are methods, systems, and non-transitory computer-readable medium for generating recommendations regarding products. A method may include determining a set of content features including one or more product attributes; determining a set of latent features; receiving a query user identifier and a query product identifier; determining a feature vector associated with the query user identifier and the query product identifier based on the set of content features and the set of latent features; determining one or more model coefficients for a linear model; and utilizing the linear model to determine a fit score for the query user identifier and the query product identifier.

Abstract: Disclosed are methods, systems, and non-transitory computer-readable medium for generating recommendations regarding products. A method may include determining a set of content features including one or more product attributes; determining a set of latent features; receiving a query user identifier and a query product identifier; determining a feature vector associated with the query user identifier and the query product identifier based on the set of content features and the set of latent features; determining one or more model coefficients for a linear model; and utilizing the linear model to determine a fit score for the query user identifier and the query product identifier.

Abstract: The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.

Abstract: Disclosed are methods, systems, and non-transitory computer-readable medium for generating recommendations regarding products. A method may include determining a set of content features including one or more product attributes; determining a set of latent features; receiving a query user identifier and a query product identifier; determining a feature vector associated with the query user identifier and the query product identifier based on the set of content features and the set of latent features; determining one or more model coefficients for a linear model; and utilizing the linear model to determine a fit score for the query user identifier and the query product identifier.

Abstract: An amide derivative inhibitor and a preparation method and an application thereof. Specifically relating to the compound shown in general formula (I), a preparation method for same, a pharmaceutical composition comprising said compound, and an application of same as an ASK inhibitor for the treatment of neurodegenerative disease, cardiovascular disease, inflammation, autoimmune and metabolic disease, each of the substituents in the general formula (I) being as defined in the description.

Abstract: Steroid derivative regulators, a method for preparing the same, and uses thereof are described. Specifically, a compound of formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator the of GABAA receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases are described, wherein the substituents of the formula (I) are as defined in the description.

Abstract: An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.

Abstract: An amide derivative inhibitor and a preparation method and an application thereof are provided. Specifically, a compound shown in general formula (I), a preparation method for same, a pharmaceutical composition containing the compound, and an application of same as an ASK inhibitor are provided. The disclosed compounds can be used for the treatment of neurodegenerative diseases, cardiovascular diseases, inflammation, autoimmune and metabolic diseases. Each of the substituents in the general formula (I) is as defined in the description.

Abstract: Disclosed are methods, systems, and non-transitory computer-readable medium for generating recommendations regarding products. A method may include determining a set of content features including one or more product attributes; determining a set of latent features; receiving a query user identifier and a query product identifier; determining a feature vector associated with the query user identifier and the query product identifier based on the set of content features and the set of latent features; determining one or more model coefficients for a linear model; and utilizing the linear model to determine a fit score for the query user identifier and the query product identifier.

Abstract: Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.

Abstract: Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.